journal article·2022-07-20Open access

Hydroxyapatite Nanoparticles for Improved Cancer Theranostics

Saeid Kargozar, Sahar Mollazadeh, Farzad Kermani, Thomas J. Webster, Simin Nazarnezhad, Sepideh Hamzehlou, Francesco Baino

Abstract

Beyond their well-known applications in bone tissue engineering, hydroxyapatite nanoparticles (HAp NPs) have also been showing great promise for improved cancer therapy. The chemical structure of HAp NPs offers excellent possibilities for loading and delivering a broad range of anticancer drugs in a sustained, prolonged, and targeted manner and thus eliciting lower complications than conventional chemotherapeutic strategies. The incorporation of specific therapeutic elements into the basic composition of HAp NPs is another approach, alone or synergistically with drug release, to provide advanced anticancer effects such as the capability to inhibit the growth and metastasis of cancer cells through activating specific cell signaling pathways. HAp NPs can be easily converted to smart anticancer agents by applying different surface modification treatments to facilitate the targeting and killing of cancer cells without significant adverse effects on normal healthy cells. The applications in cancer diagnosis for magnetic and nuclear in vivo imaging are also promising as the detection of solid tumor cells is now achievable by utilizing superparamagnetic HAp NPs. The ongoing research emphasizes the use of HAp NPs in fabricating three-dimensional scaffolds for the treatment of cancerous tissues or organs, promoting the regeneration of healthy tissue after cancer detection and removal. This review provides a summary of HAp NP applications in cancer theranostics, highlighting the current limitations and the challenges ahead for this field to open new avenues for research.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tissue Engineering Research Group (TERG), Department of Anatomy and Cell Biology, School of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran

Department of Materials Engineering, Faculty of Engineering, Ferdowsi University of Mashhad (FUM), Azadi Square, Mashhad 9177948564, Iran

Programa de Pós-Graduação em Ciência e Engenharia dos Materiais, Universidade Federal do Piauí, Teresina 64049-550, Brazil

School of Engineering, Saveetha University, Chennai 602117, India

School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin 065000, China

Genetics Laboratory, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad 9176699199, Iran

Institute of Materials Physics and Engineering, Department of Applied Science and Technology (DISAT), Politecnico di Torino, 10129 Torino, Italy

References (100+)

Show source-provided references
1. Cancer statistics, 202010.3322/caac.21590 ↗
2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries10.3322/caac.21660 ↗
3. The role of genomics in global cancer prevention10.1038/s41571-020-0428-5 ↗
4. High frequency of bone recurrence as an initial recurrence site after radical surgery in T1N3 gastric cancer: A propensity score matching analysis10.1007/s00423-021-02231-8 ↗
5. Nanotechnology in hyperthermia cancer therapy: From fundamental principles to advanced applications10.1016/j.jconrel.2016.05.062 ↗
6. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)10.1111/1759-7714.13272 ↗
7. Tumour heterogeneity and resistance to cancer therapies10.1038/nrclinonc.2017.166 ↗
8. Ali, O.A., and Mooney, D.J. (2010). Immunologically active biomaterials for cancer therapy. Cancer Immunology and Immunotherapy, Springer.10.1007/82_2010_69 ↗
9. Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook10.1002/adma.201606036 ↗
10. Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells10.1016/j.biomaterials.2016.04.030 ↗
11. Wang, X., Chang, J., and Wu, C. (2019). MoS2-based biomaterials for cancer therapy. Biomaterials in Translational Medicine, Elsevier.10.1016/B978-0-12-813477-1.00007-4 ↗
12. Recent Advances of Gold Compounds in Anticancer Immunity10.3389/fchem.2020.00543 ↗
13. HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours10.1016/j.biomaterials.2019.119728 ↗
14. A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia10.1038/s41551-019-0503-3 ↗
15. Boosting the photodynamic therapy efficiency by using stimuli-responsive and AIE-featured nanoparticles10.1016/j.biomaterials.2019.119749 ↗
16. Synthesis and characterization of Barium-Iron containing magnetic bioactive glasses: The effect of magnetic component on structure and in vitro bioactivity10.1016/j.colsurfb.2018.12.036 ↗
17. Kermani, F., Kargozar, S., Dorozhkin, S.V., and Mollazadeh, S. (2022). Calcium phosphate bioceramics for improved angiogenesis. Biomaterials for Vasculogenesis and Angiogenesis, Woodhead Publishing.10.1016/B978-0-12-821867-9.00004-4 ↗
18. Calcium Phosphate-Based Bioceramics in the Treatment of Osteosarcoma: Drug Delivery Composites and Magnetic Hyperthermia Agents10.3389/fmedt.2021.700266 ↗
19. Synthesis of nano HA/βTCP mesoporous particles using a simple modification in granulation method10.1016/j.msec.2018.11.045 ↗
20. Nanocrystalline calcium phosphate ceramics in biomedical engineering10.1016/j.msec.2006.05.018 ↗
21. Mucalo, M. (2015). Structure and properties of hydroxyapatite for biomedical applications. Hydroxyapatite (Hap) for Biomedical Applications, Woodhead Publishing.10.1016/B978-1-78242-033-0.00014-6 ↗
22. Calcium phosphates in biomedical applications: Materials for the future?10.1016/j.mattod.2015.10.008 ↗
23. Silicon-doped calcium phosphates; the critical effect of synthesis routes on the biological performance10.1016/j.msec.2020.110828 ↗
24. Improved osteogenesis and angiogenesis of theranostic ions doped calcium phosphates (CaPs) by a simple surface treatment process: A state-of-the-art study10.1016/j.msec.2021.112082 ↗
25. Crystallization behavior and density functional theory study of solution combustion synthesized silicon doped calcium phosphates10.1016/j.ceramint.2022.01.325 ↗
26. Lara-Ochoa, S., Ortega-Lara, W., and Guerrero-Beltran, C.E. (2021). Hydroxyapatite Nanoparticles in Drug Delivery: Physicochemistry and Applications. Pharmaceutics, 13.10.3390/pharmaceutics13101642 ↗
27. Calcium orthophosphate bioceramics10.1016/j.ceramint.2015.08.004 ↗
28. Additive manufacturing methods for producing hydroxyapatite and hydroxyapatite-based composite scaffolds: A review10.3389/fmats.2019.00313 ↗
29. Biomimetic hollow mesoporous hydroxyapatite microsphere with controlled morphology, entrapment efficiency and degradability for cancer therapy10.1039/C7RA09204K ↗
30. Folate-modified hydroxyapatite nanorods induce apoptosis in MCF-7 cells through a mitochondrial-dependent pathway10.1039/C9NJ03653A ↗
31. Substituted hydroxyapatites for biomedical applications: A review10.1016/j.ceramint.2015.03.316 ↗
32. 89Sr-doped hydroxyapatite nanoparticles as a potential therapeutic agent for bone tumors10.1111/ijac.13262 ↗
33. Synthesis of hollow mesoporous HAp-Au/MTX and its application in drug delivery10.1016/j.colsurfa.2019.124231 ↗
34. Doxorubicin loaded large-pore mesoporous hydroxyapatite coated superparamagnetic Fe3O4 nanoparticles for cancer treatment10.1016/j.ijpharm.2016.05.046 ↗
35. Layered nanohydroxyapatite as a novel nanocarrier for controlled delivery of 5-fluorouracil10.1016/j.ijpharm.2016.09.004 ↗
36. Luo, D., Xu, X., Iqbal, M.Z., Zhao, Q., Zhao, R., Farheen, J., Zhang, Q., Zhang, P., and Kong, X. (2021). siRNA-Loaded Hydroxyapatite Nanoparticles for KRAS Gene Silencing in Anti-Pancreatic Cancer Therapy. Pharmaceutics, 13.10.3390/pharmaceutics13091428 ↗
37. Folate conjugation improved uptake and targeting of porous hydroxyapatite nanoparticles containing epirubicin to cancer cells10.1080/10837450.2020.1725045 ↗
38. AbouAitah, K., Stefanek, A., Higazy, I.M., Janczewska, M., Swiderska-Sroda, A., Chodara, A., Wojnarowicz, J., Szałaj, U., Shahein, S.A., and Aboul-Enein, A.M. (2020). Effective Targeting of Colon Cancer Cells with Piperine Natural Anticancer Prodrug Using Functionalized Clusters of Hydroxyapatite Nanoparticles. Pharmaceutics, 12.10.3390/pharmaceutics12010070 ↗
39. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer10.1016/j.biomaterials.2011.01.027 ↗
40. Encapsulating doxorubicin-intercalated lamellar nanohydroxyapatite into PLGA nanofibers for sustained drug release10.1016/j.cap.2019.08.003 ↗
41. Hydroxyapatite-poly (vinyl alcohol) core-shell nanoparticles for dual delivery of methotrexate and gemcitabine for bone cancer treatment10.1016/j.jddst.2019.03.041 ↗
42. Iron (Fe)-doped mesoporous 45S5 bioactive glasses: Implications for cancer therapy10.1016/j.tranon.2022.101397 ↗
43. On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging10.1016/j.actbio.2018.04.040 ↗
44. Hyaluronan-directed fabrication of co-doped hydroxyapatite as a dual-modal probe for tumor-specific bioimaging10.1039/C9TB02787D ↗
45. A novel approach to breast cancer diagnosis via PET imaging of microcalcifications using 18F-NaF10.2967/jnumed.114.139170 ↗
46. Hybrid Mesoporous Silica-Based Drug Carrier Nanostructures with Improved Degradability by Hydroxyapatite10.1021/nn507485j ↗
47. Selenium-doped hydroxyapatite nanoparticles for potential application in bone tumor therapy10.1016/j.jinorgbio.2020.111334 ↗
48. Selenium-substituted hydroxyapatite particles with regulated microstructures for osteogenic differentiation and anti-tumor effects10.1016/j.ceramint.2019.04.075 ↗
49. Mono-dispersed Ba2+-doped Nano-hydroxyapatite conjugated with near-infrared Cu-doped CdS quantum dots for CT/fluorescence bimodal targeting cell imaging10.1016/j.microc.2017.05.003 ↗
50. Hafnium-doped hydroxyapatite nanoparticles with ionizing radiation for lung cancer treatment10.1016/j.actbio.2016.04.004 ↗
51. Radiosensitization induced by zinc-doped hydroxyapatite nanoparticles in breast cancer cells10.1111/ijac.13707 ↗
52. Quercetin-Loaded Luminescent Hydroxyapatite Nanoparticles for Theranostic Application in Monolayer and Spheroid Cultures of Cervical Cancer Cell Line In Vitro10.1021/acsabm.1c00255 ↗
53. Duality of iron (III) doped nano hydroxyapatite in triple negative breast cancer monitoring and as a drug-free therapeutic agent10.1016/j.ceramint.2020.03.231 ↗
54. Zirconium doped hydroxyapatite nanoparticle as a potential design for lung cancer therapy10.1016/j.ceramint.2021.06.219 ↗
55. Biocompatible europium doped hydroxyapatite nanoparticles as a biological fluorescent probe10.2174/157341310790945632 ↗
56. Paduraru, A.V., Oprea, O., Musuc, A.M., Vasile, B.S., Iordache, F., and Andronescu, E. (2021). Influence of Terbium Ions and Their Concentration on the Photoluminescence Properties of Hydroxyapatite for Biomedical Applications. Nanomaterials, 11.10.3390/nano11092442 ↗
57. Luminomagnetic Eu3+-and Dy3+-doped hydroxyapatite for multimodal imaging10.1016/j.msec.2017.08.032 ↗
58. Magnetic hydroxyapatite: A promising multifunctional platform for nanomedicine application10.2147/IJN.S147355 ↗
59. Synthesis and characterization of 159Gd-doped hydroxyapatite nanorods for bioapplications as theranostic systems10.1016/j.matchemphys.2016.06.063 ↗
60. Neodymium doped hydroxyapatite theranostic nanoplatforms for colon specific drug delivery applications10.1016/j.colsurfb.2016.05.067 ↗
61. Rare-earth (Gd3+, Yb3+/Tm3+, Eu3+) co-doped hydroxyapatite as magnetic, up-conversion and down-conversion materials for multimodal imaging
62. Gadolinium-Doped Hydroxyapatite Nanorods as T1 Contrast Agents and Drug Carriers for Breast Cancer Therapy10.1021/acsanm.8b02036 ↗
63. Synthesis, characterization and in vitro anti-cancer activity of vanadium-doped nanocrystalline hydroxyapatite10.1039/C9NJ03406D ↗
64. The hallmarks of cancer10.1016/S0092-8674(00)81683-9 ↗
65. Hallmarks of cancer: The next generation10.1016/j.cell.2011.02.013 ↗
66. Hanahan, D., and Weinberg, R.A. (2016). Biological hallmarks of cancer. Holl.-Frei Cancer Med., 1–10.10.1002/9781119000822.hfcm002 ↗
67. Nanoparticle Based Combination Treatments for Targeting Multiple Hallmarks of Cancer
68. Anti-osteosarcoma effect of hydroxyapatite nanoparticles both in vitro and in vivo by downregulating the FAK/PI3K/Akt signaling pathway10.1039/D0BM00898B ↗
69. Oxidative stress-induced apoptosis of osteoblastic MC3T3-E1 cells by hydroxyapatite nanoparticles through lysosomal and mitochondrial pathways10.1039/C7RA01008G ↗
70. Primary tumor and pre-metastatic niches co-targeting "peptides-lego" hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment10.1039/C8BM00706C ↗
71. Hydroxyapatite: Hexagonal or monoclinic?10.1021/cg900156w ↗
72. Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite10.1002/wnan.1504 ↗
73. Monoclinic hydroxyapatite10.1126/science.180.4090.1055 ↗
74. Preparation and structure refinement of monoclinic hydroxyapatite10.1006/jssc.1998.8120 ↗
75. Crystallographic structure of human tooth enamel by electron microscopy and x-ray diffraction: Hexagonal or monoclinic?10.1111/j.1365-2818.2012.03653.x ↗
76. Refinement of the hydroxyapatite structure10.1107/S0365110X58000815 ↗
77. Hydroxyapatite: A review of syntheses, structure and applications in heterogeneous catalysis10.1016/j.ccr.2017.06.009 ↗
78. Computational study of hydroxyapatite structures, properties and defects10.1088/0022-3727/48/19/195302 ↗
79. Solution combustion synthesis (SCS) of theranostic ions doped biphasic calcium phosphates; kinetic of ions release in simulated body fluid (SBF) and reactive oxygen species (ROS) generation10.1016/j.msec.2020.111533 ↗
80. A computer modelling study of the uptake, structure and distribution of carbonate defects in hydroxy-apatite10.1016/j.biomaterials.2005.09.025 ↗
81. First-principles study of vacancy formation in hydroxyapatite10.1103/PhysRevB.75.014102 ↗
82. Theoretical investigation of the defect formation mechanism relevant to nonstoichiometry in hydroxyapatite10.1103/PhysRevB.77.104106 ↗
83. Defect-Related Luminescent Hydroxyapatite-Enhanced Osteogenic Differentiation of Bone Mesenchymal Stem Cells Via an ATP-Induced cAMP/PKA Pathway10.1021/acsami.6b01103 ↗
84. Natural polysaccharide-incorporated hydroxyapatite as size-changeable, nuclear-targeted nanocarrier for efficient cancer therapy10.1039/D0BM01320J ↗
85. Synthesis methods for nanosized hydroxyapatite with diverse structures10.1016/j.actbio.2013.04.012 ↗
86. Effect of hydroxyapatite particle size, morphology and crystallinity on proliferation of colon cancer HCT116 cells10.1016/j.msec.2014.03.022 ↗
87. The in vitro and in vivo anti-melanoma effects of hydroxyapatite nanoparticles: Influences of material factors10.2147/IJN.S184792 ↗
88. Self-Activated Fluorescent Hydroxyapatite Nanoparticles: A Promising Agent for Bioimaging and Biolabeling10.1021/acsbiomaterials.6b00169 ↗
89. Designing biocompatible and multicolor fluorescent hydroxyapatite nanoparticles for cell-imaging applications10.1016/j.mtchem.2019.100211 ↗
90. Luminescence enhanced Eu3+/Gd3+ co-doped hydroxyapatite nanocrystals as imaging agents in vitro and in vivo10.1021/acsami.6b01814 ↗
91. Eu/Tb codoped spindle-shaped fluorinated hydroxyapatite nanoparticles for dual-color cell imaging10.1039/C6NR02137A ↗
92. Different inhibitory effect and mechanism of hydroxyapatite nanoparticles on normal cells and cancer cells in vitro and in vivo10.1038/srep07134 ↗
93. Inhibitory effect comparison of the needle, spherical, and mesoporous hydroxyapatite nanoparticles on MCF-7 breast cancer cell line proliferation: An in vitro assay
94. Nanohydroxyapatite Exerts Cytotoxic Effects and Prevents Cellular Proliferation and Migration in Glioma Cells10.1093/toxsci/kfz019 ↗
95. Effect of hydroxyapatite nanoparticles on the ultrastructure and function of hepatocellular carcinoma cells in vitro10.1088/1748-6041/1/1/006 ↗
96. Cytotoxicity of hydroxyapatite nanoparticles is shape and cell dependent10.1007/s00204-012-0827-1 ↗
97. Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells10.1016/j.biomaterials.2009.09.088 ↗
98. Mitochondria-Targeted Hydroxyapatite Nanoparticles for Selective Growth Inhibition of Lung Cancer in Vitro and in Vivo10.1021/acsami.6b06094 ↗
99. p53 reaction to apoptosis induced by hydroxyapatite nanoparticles in rat macrophages10.1002/jbm.a.31892 ↗
100. Differential cytotoxicity and particle action of hydroxyapatite nanoparticles in human cancer cells10.2217/nnm.12.217 ↗